Eurofins Launches CE-IVD Marked Rapid POC Testing Devices to Identify Past Exposure to COVID-19 in 10 Minutes
By HospiMedica International staff writers Posted on 02 Jul 2020 |
Image: Eurofins Launches CE-IVD Marked Rapid POC Testing Devices to Identify Past Exposure to COVID-19 in 10 Minutes (Photo courtesy of Eurofins Technologies)
Eurofins Technologies (Budapest, Hungary) has launched CE-IVD marked rapid point-of-care testing devices to identify a person’s past exposure to COVID-19 (SARS-CoV-2) in only 10 minutes.
The serology-based, finger-prick tests detect virus antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms. The CE-IVD marked INgezim COVID-19 CROM dual-recognition immunochromatographic assays determine the presence of total antibodies (IgG, IgA and IgM) specific to SARS-CoV-2 in a single blood, serum, and plasma sample by using nucleoprotein (N protein) as an antigen for detection of virus antibodies. The N protein is one of the most abundant early-onset proteins of the virus and is highly immunogenic, making it a reliable antigen candidate for the diagnosis of SARS-CoV-2. The CE-IVD marked kits include all materials required to perform the finger-prick test. The analysis can be performed outside of the laboratory, representing significant cost and time savings compared to other labor- and equipment-intensive methods.
Additionally, Eurofins has also launched Eurofins COVID-19 Sentinel RT-PCR environmental surfaces tests which can contribute to detecting asymptomatic virus spreaders. Through a comprehensive range of testing solutions, including waste water testing, work environment surface testing and worn mask testing, Eurofins COVID-19 Sentinel provides an early warning of the presence of SARS-CoV-2 at a given site (e.g. a city, factories, education, government and public service sites, nursing homes), before the virus spreads too broadly. If positive results are found employees present in the rooms tested can be isolated and advised to get tested by clinical RT-PCR. The affordable, easily organized and non-invasive Eurofins COVID-19 Sentinel program allows governments and companies to early detect the presence of asymptomatic and pre-symptomatic virus carriers, at times before anyone is aware of the issue, and to assess effectiveness of workplace COVID-19 management plans.
The serology-based, finger-prick tests detect virus antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms. The CE-IVD marked INgezim COVID-19 CROM dual-recognition immunochromatographic assays determine the presence of total antibodies (IgG, IgA and IgM) specific to SARS-CoV-2 in a single blood, serum, and plasma sample by using nucleoprotein (N protein) as an antigen for detection of virus antibodies. The N protein is one of the most abundant early-onset proteins of the virus and is highly immunogenic, making it a reliable antigen candidate for the diagnosis of SARS-CoV-2. The CE-IVD marked kits include all materials required to perform the finger-prick test. The analysis can be performed outside of the laboratory, representing significant cost and time savings compared to other labor- and equipment-intensive methods.
Additionally, Eurofins has also launched Eurofins COVID-19 Sentinel RT-PCR environmental surfaces tests which can contribute to detecting asymptomatic virus spreaders. Through a comprehensive range of testing solutions, including waste water testing, work environment surface testing and worn mask testing, Eurofins COVID-19 Sentinel provides an early warning of the presence of SARS-CoV-2 at a given site (e.g. a city, factories, education, government and public service sites, nursing homes), before the virus spreads too broadly. If positive results are found employees present in the rooms tested can be isolated and advised to get tested by clinical RT-PCR. The affordable, easily organized and non-invasive Eurofins COVID-19 Sentinel program allows governments and companies to early detect the presence of asymptomatic and pre-symptomatic virus carriers, at times before anyone is aware of the issue, and to assess effectiveness of workplace COVID-19 management plans.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans